实时三维超声心动图评价择期PCI对急性心肌梗死左心室重构的价值  

Evaluation on the ventricular remodeling after selective percutaneous coronary intervention for patients with acute myocardial infarction using real time three dimensional echocardiography

作　　者：邹淑丽[1] 田英军[1] 翟莉[2] 焦健[1] 宋艳[1] 

机构地区：[1]武警山东总队医院医学影像中心,山东济南250014 [2]武警北京总队第二医院内一科,北京100037

出　　处：《中国介入影像与治疗学》2010年第6期636-639,共4页Chinese Journal of Interventional Imaging and Therapy

摘　　要：目的应用实时三维超声心动图(RT-3DE)评价择期经皮冠状动脉介入治疗术(PCI)对急性心肌梗死患者心室重构的影响。方法收集初次急性心肌梗死患者90例,根据治疗方法不同,分为择期PCI组(44例)和药物治疗组(46例)。于入院时和3个月时应用RT-3DE测量两组患者左心室舒张末期容积(LVEDV)、收缩末期容积(LVESV)、射血分数(LVEF)。结果择期PCI组患者的LVEDV、LVESV各测值明显小于药物治疗组(P<0.01),而LVEF明显大于药物治疗组(P<0.01);LVEF的减小与LVEDV的增大呈负相关(r=-0.653)。结论择期PCI治疗能显著减轻急性心肌梗死患者的心室重构并改善患者的心脏功能。应用RT-3DE能够更清晰地显示心腔的立体结构,更好地测定LVEDV、LVESV。Objective To evaluate the ventricular remodeling after selective percutaneous coronary intervention （PCI） for patients with acute myocardial infarction using real time three dimensional echocardiography （RT-3DE）.Methods Ninety patients with acute myocardial infarction for the first time were collected and divided into selective PCI group （44 cases） and conventional medical treatment group （46 cases）.The left ventricular end diastolic volume （LVEDV）,end systolic volume （LVESV） and ejection fraction （LVEF） were measured with real time three dimensional echocardiography on the admission to hospital and 3 months later.Results LVEDV and LVESV in the selective PCI groups were significantly less than those in the conventional medical treatment group （P0.01）,while LVEF in the selective PCI group was significantly higher （P0.01）.There was negative correlation between the decrease of LVEF and increase of LVEDV （r=-0.653）.Conclusion PCI can reduce ventricular remodeling and improve cardiac function.The application of RT-3DE can visualize clearer dynamic morphology views of heart,measure LVEDV and LVESV more accurately and correctly reflect the ventricular remodeling and cardiac function of the patients with acute myocardial infarction.

关 键 词：超声心动描记术 心肌梗死 心室重构 

分 类 号：R542.22[医药卫生—心血管疾病] R540.45[医药卫生—内科学]